Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.36 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | GRM8 | O00222 | 1/20 | 0.30 |
| ▸ | GRM6 | O15303 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209199 | 1.00 | GRM2 (0.36) | GRM2GRM3GRIK1GRIK2GRIK3 | |
| SCHEMBL13016442 | 0.83 | — | — | |
| SCHEMBL15100509 | 0.83 | — | — | |
| SCHEMBL15606749 | 0.82 | MAOB (0.34) | — | |
| SCHEMBL12885948 | 0.82 | MAOB (0.34) | — | |
| SCHEMBL16564732 | 0.82 | MAOB (0.34) | — | |
| SCHEMBL15113268 | 0.80 | DPP4 (0.31) | — | |
| SCHEMBL18921018 | 0.80 | EPHX2 (0.33) | GRM2GRM3 | |
| SCHEMBL29475199 | 0.80 | EPHX2 (0.33) | GRM2GRM3 | |
| SCHEMBL16489099 | 0.80 | GRM2 (0.31) | GRM2GRM3APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4289842-A1 | PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF | Hepagene Therapeutics (HK) Limited (HK) | 2023-12-13 | — | — | EP | disclosed |
| CN-117083279-A | Oxazepine compounds and their use in the treatment of cancer | 基因泰克公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2022166923-A1 | PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF | 和博医药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| CN-108602807-B | Heterocyclic sulfonamide derivatives and drugs containing the same | EA制药株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| WO-2020001592-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USE THEREOF | 河南天晟泰丰医药科技有限公司 | 2020-01-02 | — | — | WO | disclosed |
| EP-3074392-B1 | PROCESSES FOR PREPARING DIHYDROPYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-04-03 | — | — | EP | disclosed |
| EP-3074394-B1 | PROCESSES FOR PREPARING DIHYDROPYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-02-20 | — | — | EP | disclosed |
| US-9643962-B2 | Processes for preparing dihydropyrimidine derivatives and intermediates thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-05-09 | — | — | US | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7981891-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2137177-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, CDK1 | GRM2 4043/4885GRM3 4032/4885GRIK1 1539/4885 |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | GRM2 4043/4885GRM3 4032/4885GRIK1 1539/4885 |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | GRM2 4043/4885GRM3 4032/4885GRIK1 1539/4885 |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | GRM2 4043/4885GRM3 4032/4885GRIK1 1539/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | GRM2 1169/4885GRM3 2008/4885GRIK1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.